Mochida: Application filed in Japan for an additional indication for Treprost inhalation solution for pulmonary hypertension associated with interstitial lung disease or combined pulmonary fibrosis and emphysema

Mochida Pharmaceutical Co., Ltd. announced that Mochida filed an application for approval of an additional indication for Treprost Inhalation Solution 1.74mg (generic name: treprostinil; development code: MD-711) for pulmonary hypertension (PH) associated with interstitial lung disease (ILD) or combined pulmonary fibrosis and emphysema (CPFE), to the Japanese Ministry of Health, Labour and Welfare (MHLW)